Marisa Wexler is a senior science writer for Myasthenia Gravis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myasthenia gravis topics.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News